Treating rattlesnake envenomation has both short-term and long-term considerations1,2

Patients treated with a single Fab antivenom remain at risk after initial control1

Image module

A PK mismatch may lead to late coagulopathy1

  • Some venom components take significantly longer to clear than unbound single Fab antivenom fragments3
  • A depot of unneutralized venom can remain in the body after initial control, resulting in prolonged absorption3
  • Late coagulopathy can be as severe or worse than the presenting coagulopathy1

Late coagulopathy is a persistent concern with single Fab antivenom1,4

Late coagulopathy=recurrent or late-onset coagulopathy; long-term=subacute phase rattlesnake envenomation; PK=pharmacokinetic; short-term=acute phase rattlesnake envenomation

Important Safety Information

ANAVIP® [Crotalidae Immune F(ab’)2 (Equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.




The most common adverse reactions observed in more than 2 percent of patients in the clinical trials for ANAVIP were: pruritus, nausea, rash, arthralgia, peripheral edema, erythema, headache, myalgia, pain in extremity, and vomiting.


ANAVIP may cause allergic reactions.

Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Monitor patients with follow-up visits for signs and symptoms of delayed allergic reactions or serum sickness (rash, fever, myalgia, arthralgia, pruritus, urticarial rash) and treat appropriately if necessary.

Transmissible Infectious Agents
ANAVIP is made from equine (horse) plasma and may therefore carry a risk of transmitting infectious agents, e.g., viruses.

Reactions to Cresol
Trace amounts of cresol from the manufacturing process are contained in ANAVIP. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.

See Full Prescribing Information